Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Non-Current Deferred Tax Liability (2019 - 2024)

Historic Non-Current Deferred Tax Liability for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to -$30.5 million.

  • Pharming's Non-Current Deferred Tax Liability fell 263.1% to -$30.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$30.5 million, marking a year-over-year decrease of 263.1%. This contributed to the annual value of -$30.5 million for FY2024, which is 263.1% down from last year.
  • Per Pharming's latest filing, its Non-Current Deferred Tax Liability stood at -$30.5 million for Q4 2024, which was down 263.1% from -$29.8 million recorded in Q4 2023.
  • Pharming's 5-year Non-Current Deferred Tax Liability high stood at -$21.2 million for Q4 2021, and its period low was -$30.9 million during Q4 2020.
  • For the 5-year period, Pharming's Non-Current Deferred Tax Liability averaged around -$27.1 million, with its median value being -$29.8 million (2023).
  • Per our database at Business Quant, Pharming's Non-Current Deferred Tax Liability soared by 3144.69% in 2021 and then tumbled by 2954.77% in 2023.
  • Pharming's Non-Current Deferred Tax Liability (Quarter) stood at -$30.9 million in 2020, then surged by 31.45% to -$21.2 million in 2021, then dropped by 8.28% to -$23.0 million in 2022, then fell by 29.55% to -$29.8 million in 2023, then fell by 2.63% to -$30.5 million in 2024.
  • Its Non-Current Deferred Tax Liability was -$30.5 million in Q4 2024, compared to -$29.8 million in Q4 2023 and -$23.0 million in Q4 2022.